CathWorks is developing an image-based functional flow reserve (FFR) measurement during coronary catheterization, replacing the pressure-wire based, drug-induced measurement currently performed. CathWorks angiogram-based FFR (FFRangio) has met the need for a less invasive FFR assessment tool, to improve real-time functional assessment leading to treatment decisions, and to make coronary catheterization procedures safer, shorter, more accurate and comprehensive.

Medical Device
Private
Visit Website
Additional Portfolio Companies
Adicet Bio
ARTSaVIT
BioBlast Pharma
Cathworks
cCAM Biotherapeutics
CheckCap
Eloxx Pharmaceuticals
Enlivex Therapeutics
Entera Bio
Eyevensys
EyeYon
Hairstetics
Headsense
Keros Therapeutics
Kite Pharma
Leap Therapeutics
LogicBio Therapeutics
Metabomed
NovellusDX
Novus Therapeutics
Nutrinia
Ocon Medical
PACT Pharma
Pi Therapeutics
Protalix
Raziel Therapeutics
ReWalk
StimatixGI
Sweetch
TargEDys
UroGen
V-Wave
Zolex Therapeutics
August 27, 2015